Past ASX announcements

2023 ASX Announcements

Notification regarding unquoted securities – IMC (12/07/2023)

Immuron Business Update - Ateria Health has launched Juvia™ in Australia - Letter to Shareholders (11/07/2023)

Immuron Chairman Transition (30/06/2023)

Letter to Shareholders (22/06/2023)

Immuron CEO, Steven Lydeamore presents at LD Micro (07/06/2023)

Immuron Initiates Recruitment of Travelan Clinical Study (30/05/2023)

FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic (08/05/2023)

Immuron CEO Steven Lydeamore to present at Coffee Microcaps (02/05/2023)

Q3 FY23 Business Update Presentation (19/04/2023)

Q3 FY23 Business Update Webinar (11/04/2023)

Immuron Q3 Sales reach 150% of 1H Sales (06/04/2023)

Appendix 4D and Half Year Report FY2023 (28/02/2023)

Business Update Presentation (28/02/2023)

Immuron CEO Steven Lydeamore to host investor webinar (15/02/2023)

Immuron and US NMRC respond to CampETEC FDA Clinical Hold (25/01/2023)

US DOD Travelan Clinical Field Study Recruitment Milestone (18/01/2023)

Immuron Receives European Patent on Drug Composition (17/01/2023)

2022 ASX Announcements

Immuron Receives FDA Approval for Travelan IND Application (23/12/2022)

Immuron Submits IND Application To FDA for Travelan (05/12/2022)

Amended Constitution of Immuron Limited (01/12/2022)

Results of Annual General Meeting (21/11/2022)

Immuron AGM Presentation (21/11/2022)

Immuron completes strategic investment in Ateria Health (16/11/2022)

Immuron CEO Steven Lydeamore to present at AusBioInvest  (26/10/2022)

Notice of Annual General Meeting/Proxy Form (21/10/2022)

Immuron investment in leading gut health biotech Ateria Health (13/10/2022)

Immuron Executes Travelan Clinical Trial Agreement Pharmaron (4/10/2022)

Appendix 4G – FY 30 June 2022 (09/09/2022)

FY22 Results and Business Update Presentation (31/08/2022)

Appendix 4E and Preliminary Final Report (31/08/2022)

Immuron CEO, Steven Lydeamore, to host an investor webinar (29/08/2022)

Immuron Update on IMM-124E SARS-CoV-2 Research (19/08/2022)

Update on IND Application for Campylobacter ETEC Therapeutic (26/07/2022)

North American Travelan Sales up 494%, Global sales up 431% (11/07/2022)

European Patent Notification on Drug Composition for CDI (07/07/2022)

Change of Director's Interest Notice – DP (04/07/2022)

Notification regarding unquoted securities - IMC (01/07/2022)

Change of Director's Notice (15/06/2022)

Notification of cessation of securities (14/06/2022)

Notification of cessation of securities (10/06/2022)

Change in substantial holding (25/05/2022)

US DoD NMRC files IND application with FDA (11/05/2022)

US DoD Uniformed Services University Clinical Update (09/05/2022)

Appointment of Mr Steven Lydeamore as Chief Executive Officer (05/05/2022)

Immuron Q3 Global Sales up 216% YoY (27/04/22)

Immuron new MTEC project proposal (19/04/22)

Initial Director’s Interest Notice (16/03/2022)

Appointment of Paul Brennan as Non-Executive Director (16/03/2022)

Half Yearly Report and Accounts (25/02/22)

Response to ASX query (24/01/22)

Changes in substantial holding (24/01/22)

Immuron receives $306,154 R&D Tax Concession Refund (17/01/22)

Immuron receives European patent on Drug to treat Diarrhoea (13/01/22)

Change in substantial holding (13/01/22)

Immuron awarded $6.2 million US DoD funding for Travelan (12/01/22)

Change in substantial holding (6/01/22)

 

2021 ASX Announcements

Application for quotation of securities - IMC (17/12/21)

Proposed issues of securites (16/12/21)

Investor Presentation (16/12/21)

Results of Annual General Meeting (15/12/21)

Change in substantial holding (1/12/21)

Notice of Annual General Meeting/ Proxy Form (16/11/21)

US DoD Travelan Clinical Update (15/11/21)

Jobkeeper Payment Notification (11/11/21)

US DoD Naval Medical Research Center Clinical Update (10/11/21)

Notification regarding unquoted securities - IMC (5/11/21)

Application for quotation of securities - IMC (5/11/21)

Immuron filed XBRL data with the SEC (3/11/21)

Form 20-F filed with the SEC (29/10/21)

Amended Appendix 3H (27/10/21)

Notification of cessation of securities - IMC (26/10/21)

Change in substantial holding (20/10/21)

Change in substantial holding (15/10/21)

IMM124E Demonstrates Antiviral T-Cell Immunity (8/10/21)

Appendix 4G (30/09/21)

Corporate Governance Statement (30/09/21)

Annual Report to Shareholders (30/09/21)

Director Resignation - Peter Anastasiou (24/09/21)

Reinstatement to Official Quotation (23/9/21)

Immuron Planned Acquisition of R&D Vaccine Company (23/9/21)

Preliminary Final Report (31/08/21)

Market Update (07/07/21)

Market Update (8/06/21)

Change in Substantial Holding (3/06/21)

Suspension from Official Quotation (31/05/21)

Trading Halt (27/05/21)

Pause in Trading (27/05/21)

Change in Substantial Holding (20/05/21)

IMM124E May Offer New Modality for Inhibition of SARS-CoV-2 (13/05/21)

Half Yearly Reports and Accounts (25/02/21)

Change of Director's Notice (9/02/21)

2020 ASX Announcements

Immuron Sars-CoV-2 Research Agreement with Monash University (15/12/20)

Change of Director's Notice (26/11/20)

Immuron receives AUD $358,280 R&D tax concession refund (24/11/20)

708A notice (18/11/20)

Appendix 3G (17/11/20)

Change of Director's Interest Notivce (x5) (17/11/20)

Change in substantial holding (16/11/20)

Appendix 2A (13/11/20)

Appendix 3G (13/11/20)

Proposed Issue of Securities (13/11/20)

US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine (9/11/20) 

Results of Meeting (29/10/20)

2020 AGM Presentation (29/10/20)

Immuron filed XBRL data with the SEC (29/10/20)

Form 20-F filed with the SEC (29/10/20)

Change in substantial holding (19/10/20)

Immuron Travelers' Diarrhea market update (13/10/20)

Time of AGM clarification (30/09/20)

Corporate Governance Statement (25/09/20)

Notice of Annual General Meeting/Proxy Form (25/09/20)

Appendix 4G (25/09/20)

Annual Report to shareholders (25/09/20)

Change in substantial holding (16/09/20)

Change in substantial holding (04/09/20)

Appendix 4E and 2020 Financial Report (01/09/20) 

Change in substantial holding (28/08/20) 

Change of Director's Interest Notice (PA&SA) (21/08/20)

Change in substantial holding (21/08/20)

Change in substantial holding (19/08/20)

Change in substantial holding (12/08/20)

Change in substantial holding (05/08/20)

Change in substantial holding (31/07/20)

Appendix 2A and 708A Notice (29/07/20)

Proposed issue of Securities – IMC (29/07/20)

Change in substantial holding (28/07/20)

Proposed issue of Securities - IMC (27/07/20)

US SEC Form 6-K Filing (24/07/20) 

Prospectus Supplement (24/07/20)

Appendix 2A and 708A Notice (24/07/20)

Closing of US$20 Million Registered Direct Offering (24/07/20) 

Proposed issue of Securities – IMC (23/07/20) 

Immuron Announces US$20.0 Million Registered Direct Offering (22/07/20) 

Immuron Reports Neutralizing activity Against SARS-CoV-2 (21/07/20)

US DoD Receives FDA Guidance on clinical development plans (20/07/20)  

Appendix 3G (03/07/20)

Appendix 2A and 708A notice (03/07/20)

Proposed issue of Securities – IMC (01/07/20)

Change in substantial holding (26/06/20)

Change in substantial holding (25/06/20)

Change of Director's Interest Notice (RA) (23/06/20)

Change of Director's Interest Notice (DP) (23/06/20)

Appendix 2A and 708A notice (23/06/20)

Change in substantial holding (23/06/20)

Proposed issue of Securities – IMC (22/06/20)

Proposed issue of Securities – IMC (22/06/20)

Change in substantial holding (22/06/20)  

IMC & CSIRO to produce oral therapeutic for DoD evaluation (19/06/20)

Change in substantial holding (GL) (19/06/20)

Change of Director's Interest Notice PA (19/06/20)

Change in substantial holding (19/06/20)

Change in substantial holding (18/06/20)

Change in substantial holding (17/06/20)

Appendix 2A and 708A notice (16/06/20)

Ceasing to be a substantial holder (16/06/20)

Change in substantial holding (16/06/20)

Proposed issue of Securities – IMC (15/06/20)  

Change of Director's Interest Notice (DP) (12/06/20)

Response to ASX Price Query (10/06/20)

Pause in Trading (10/06/20)  

US Defense requests FDA meeting (09/06/20)

Immuron Board Relinquish Cash Payment of Fees (27/04/20)  

Immuron Global Sales Up 60% (20/04/20)  

Final Director's Interest Notice (GJ) (26/03/20) 

Resignation of Managing Director and cuts amid Covid19 (25/03/20)  

Immuron Provides Update on First Half of FY20 Results (02/03/20)

Half Yearly Report and Accounts (26/02/20)

Change in substantial holding (12/02/20)

North American Travelan sales up 98% to Dec 2019 (28/01/20)

Change of Share Registry (20/01/20)

Immuron CEO to present at Biotech Conference in SFO (08/01/20)